Novel Promising Therapeutic Agents in Multiple Sclerosis

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|1|3|218-224

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.1, Iss.3, 2007-11, pp. : 218-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 5, Iss. 1, 2011-01 ,pp. : 66-80

Bentham Science Publishers

Access to resources Recommend Favorite

Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 2, 2007-06 ,pp. : 142-151

Bentham Science Publishers

Access to resources Recommend Favorite

Microporation Techniques for Enhanced Delivery of Therapeutic Agents

By  

Recent Patents on Drug Delivery & Formulation, Vol. 4, Iss. 1, 2010-01 ,pp. : 1-17

Bentham Science Publishers

Access to resources Recommend Favorite

Structural and Functional Properties, Chaperone Activity and Posttranslational Modifications of Alpha-Crystallin and its Related Subunits in the Crystalline Lens: N-acetylcarnosine, Carnosine and Carcinine act as Alpha- Crystallin/Small Heat Shock Protein Enhancers in Prevention and Dissolution of Cataract in Ocular Drug Delivery Formulations of Novel Therapeutic Agents

By  

Recent Patents on Drug Delivery & Formulation, Vol. 6, Iss. 2, 2012-08 ,pp. : 107-148

Bentham Science Publishers

Access to resources Recommend Favorite

Chemokines as Novel Therapeutic Targets in Autoimmune Thyroiditis

By  

Recent Patents on DNA & Gene Sequences, Vol. 4, Iss. 1, 2010-01 ,pp. : 52-57

Bentham Science Publishers

Access to resources Recommend Favorite